Table 1.
Summary of the most relevant tracers available for the evaluation of recurrent PCa.
| Tracer | Target | Technique | Use | Site of PCa recurrence | Main advantage | Main limitation |
|---|---|---|---|---|---|---|
| 18F/11C-choline | Cell membrane synthesis and phospholipid metabolism | PET/CT PET/MR | Established | Any | Sensitivity | Lack of specificity for PCa |
| 18F-NaF | Bone remodeling | PET/CT PET/MR | Established | Bone metastases | Sensitivity | Lack of specificity for PCa |
| 99mTc-diphosphonates | Bone remodeling | SPECT/CT | Established | Bone metastases | Sensitivity | Lack of specificity for PCa |
| 68Ga-HBED-CC | PSMA | PET/CT PET/MR | Under evaluation | Any | Preliminary data showing higher sensitivity than choline-based tracers | To be assessed |
| 111In–111In Capromab Pendetide (ProstaScint®) | PSMA | SPECT/CT | Established | Any | Specificity | Spatial resolution |
PCa, prostate cancer; PSMA, prostate-specific membrane antigen.